Developing the guidance involved active participation from all stakeholder groups including patients, medical experts, academics and biopharmaceutical industry representatives. This guidance has been submitted to FDA.
Download
Patient Resources
Guidance for Industry AL Amyloidosis – Developing Drugs for Industry
Related Content
